Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis

Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis

(2021) Beth A. Smith et al.   Journal of Cystic Fibrosis

Trikafta and Psychopathology in Cystic Fibrosis: A Case Report

(2020) William Tindell et al.   PSYCHOSOMATICS

Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review

(2020) Renée V. E. Dagenais et al.   Journal of Clinical Medicine

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

(2018) Dominic Keating et al.   NEW ENGLAND JOURNAL OF MEDICINE

Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis

(2017) Cameron J. McKinzie et al.   Journal of Cystic Fibrosis

International Committee on Mental Health in Cystic Fibrosis: Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety

(2015) Alexandra L Quittner et al.   THORAX